David Sinclair returns to Diamandis. Harvard Professor David Sinclair, author of Lifespan and one of the world's most renowned longevity researchers, appeared about three weeks ago on Peter Diamandis's Moonshots podcast, recorded live at the Abundance360 Summit 2026. This is his first conversation on the microphone since the FDA approval for clinical trials of Yamanaka factors, and in it he delves into his personal protocol in its 2026 version, the timelines he gives for the first longevity pill, and what has changed in the scientific understanding of reversing aging in the last two years.
What the video is about
The conversation between Sinclair and Diamandis moves between the current state of research and future expectations, covering four main axes:
- The first longevity pill: Sinclair gives a specific estimate for when he expects FDA approval for the first drug officially labeled as "anti-aging," rather than just a treatment for a specific chronic disease.
- Yamanaka factors after FDA approval: What the approval of human clinical trials means, which organ is at the forefront, and why it was chosen first.
- Personal protocol 2026: Sinclair reviews his daily stack, what he added this year, what he gave up, and how he balances supplement intake with lifestyle interventions like fasting and cold exposure.
- Biological age clocks: Which clock he recommends for measurement today, how his own results have changed, and why he warns against obsession with numbers without clinical context.
Why you should watch
Sinclair is one of the figures defining the public conversation around longevity, but he also critiques himself honestly. In this conversation, he admits where he was wrong in the previous decade and what he is changing in 2026 in light of accumulated research. The video is especially suitable for those who have followed the aging field for years and want a concise update on changes to his protocol, as well as for those looking for a single, organized source to understand where the industry stands in mid-2026, after Yamanaka factors have become a clinical pathway for the first time, not just a laboratory promise.
Enjoy watching!
💬 תגובות (0)
היו הראשונים להגיב על המאמר.